Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).

James R. Berenson(Oncotherapeutics (United States)), Jesús G. Berdeja(Tennessee Oncology), Robert M. Rifkin(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Morton Coleman(Cornell University), Alberto Bessudo(California Cancer Associates for Research and Excellence), Priti Patel(AstraZeneca (United States)), Wael A. Harb, Sandra Dixon(Amgen (United States)), Alan Cartmell(Newcastle University), Ralph V. Boccia(Center for Cancer and Blood Disorders), Roger M. Lyons(Hematology Oncology Associates)
Journal of Clinical Oncology
May 20, 2015
10.1200/jco.2015.33.15_suppl.8527
Cited by 4

Related Papers

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795